January 30, 2018 04:39 PM EST

Counting its remaining cash, Vical axes 40 staffers and circles wagons around two Phase II assets

Just days after Vical $VICL and its partners at Astellas announced that their late-stage study of the CMV vaccine ASP0113 had failed badly, the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Count­ing its re­main­ing cash, Vi­cal ax­es 40 staffers and cir­cles wag­ons around two Phase II as­sets